Clinical characteristics of monoclonal CLL cases versus CLL with 2 or more B-cell clones
. | 2 or more B-cell clones . | . | . | . | |
|---|---|---|---|---|---|
. | CLL + CLL, n = 18 . | CLL + non-CLL, n = 15 . | Monoclonal CLL, n = 366 . | P . | |
| Age, y | 66 ± 11 | 77 ± 8* | 71 ± 10 | .05 | |
| Sex, % | NS | ||||
| Female | 22 | 40 | 38 | ||
| Male | 78 | 60 | 62 | ||
| ECOG greater than 2, % | 7 | 7 | 2 | NS | |
| Binet clinical stage, % | NS | ||||
| A | 69 | 67 | 81 | ||
| B or C | 31 | 33 | 19 | ||
| B symptoms, % | 9 | 50* | 14 | .03 | |
| Adenopathies, % | 56 | 33 | 36 | NS | |
| Hepatomegaly, % | 12 | 7 | 13 | NS | |
| Splenomegaly, % | 37 | 27 | 16* | .02 | |
| Monoclonal component, % | 0 | 15* | 2 | .002 | |
| Diffuse pattern of BM infiltration, % | 44* | 0 | 19 | .05 | |
| % of cases requiring treatment | 47 | 50 | 30 | NS | |
| % of cases requiring treatment 18 mo after diagnosis | 40 | 50 | 26 | .03 | |
| % of cases with associated neoplasias | 0 | 0 | 4 | NS | |
| % deaths due to PD | 6 | 7 | 4 | NS | |
. | 2 or more B-cell clones . | . | . | . | |
|---|---|---|---|---|---|
. | CLL + CLL, n = 18 . | CLL + non-CLL, n = 15 . | Monoclonal CLL, n = 366 . | P . | |
| Age, y | 66 ± 11 | 77 ± 8* | 71 ± 10 | .05 | |
| Sex, % | NS | ||||
| Female | 22 | 40 | 38 | ||
| Male | 78 | 60 | 62 | ||
| ECOG greater than 2, % | 7 | 7 | 2 | NS | |
| Binet clinical stage, % | NS | ||||
| A | 69 | 67 | 81 | ||
| B or C | 31 | 33 | 19 | ||
| B symptoms, % | 9 | 50* | 14 | .03 | |
| Adenopathies, % | 56 | 33 | 36 | NS | |
| Hepatomegaly, % | 12 | 7 | 13 | NS | |
| Splenomegaly, % | 37 | 27 | 16* | .02 | |
| Monoclonal component, % | 0 | 15* | 2 | .002 | |
| Diffuse pattern of BM infiltration, % | 44* | 0 | 19 | .05 | |
| % of cases requiring treatment | 47 | 50 | 30 | NS | |
| % of cases requiring treatment 18 mo after diagnosis | 40 | 50 | 26 | .03 | |
| % of cases with associated neoplasias | 0 | 0 | 4 | NS | |
| % deaths due to PD | 6 | 7 | 4 | NS | |
Results expressed as percentage of cases. Values for age presented as mean ± SD. PD indicates progressive disease. NS indicates that no statistically significant differences were observed between groups (P > .05). ECOG indicates the performance status scaled from 0 to 5 by the Eastern Cooperative Oncology Group.
Statistically significantly different from the other 2 groups of patients.